GO
Loading...

Drug Retail

More

  • GlaxoSmithKline CEO Sir Andrew Witty, explains the large portfolio of vaccinations his company provides, and the value added from the company's acquisition of Novartis' vaccination business.

  • Novartis acquisition adds 'tremendous value'  Tuesday, 22 Apr 2014 | 6:45 AM ET

    GlaxoSmithKline CEO Sir Andrew Witty, discusses the benefit to shareholders from his company's acquisition of Novartis' vaccination business, as well as its oncology unit.

  • Sarepta CEO 'optimistic' for muscle drug approval  Monday, 21 Apr 2014 | 2:07 PM ET

    Sarepta Therapeutics CEO Chris Garabedian discusses the prospects for what he calls a "potential accelerated approval" for its Duchenne muscular dystrophy drug Eteplirsen.

  • Sarepta muscle drug faces challenges  Monday, 21 Apr 2014 | 2:04 PM ET

    Sarepta Therapeutics is developing a drug for Duchenne muscular dystrophy. Its CEO Chris Garabedian discusses challenges the drug Eteplirsen has faced before the FDA.

  • Walgreens urged to leave US to gain tax benefit Monday, 14 Apr 2014 | 8:40 AM ET

    Walgreens has come under pressure from an influential group of its shareholders, who want the US pharmacy chain to consider relocating to Europe, in what would be one of the largest tax inversions ever attempted. The FT reports.

  • Hep C breakthrough  Thursday, 10 Apr 2014 | 2:53 PM ET

    CNBC contributor Barbara Ryan provides insight into new guidelines from the World Health Organization, which strongly endorses two new hepatitis c drugs.

  • Flu drug stockpiles a waste of money: Report Thursday, 10 Apr 2014 | 6:27 AM ET

    The U.K. and U.S. governments spent millions stockpiling a flu drug that is no better than paracetamol, according to a new report.

  • Ultragenyx is now up around 150 percent from its IPO price. Its CEO Dr. Emil Kakkis provides insight on the development of its drugs, and just how committed the company is to treating patients with the diseases its drugs treat.

  • Injectable cholesterol drugs to face challenges  Monday, 31 Mar 2014 | 2:51 PM ET

    FTI Consulting managing director Barbara Ryan provides insight on new drugs showing dramatic improvement in the standard of care for high cholesterol.

  • New class of cholesterol drugs  Monday, 31 Mar 2014 | 1:19 PM ET

    CNBC's Dominic Chu reports on news out about a special new drug that could combat cholesterol.

  • CNBC's All-America survey: Obamacare & minimum wage  Wednesday, 26 Mar 2014 | 2:16 PM ET

    CNBC's Steve Liesman reports how participants of CNBC's All-America Economic Survey view Obamacare, and raising the minimum wage.

  • CNBC's All-America survey: Marijuana views  Wednesday, 26 Mar 2014 | 1:22 PM ET

    CNBC's Steve Liesman reports 56 percent of participants supported the legalization of marijuana in their town.

  • Why drug treatment prices vary  Wednesday, 26 Mar 2014 | 1:08 PM ET

    The U.S. government is prohibited by law from negotiating drug prices, reports CNBC's Sheila Dharmarajan.

  • NJ pot bill: Garden State going green?  Tuesday, 25 Mar 2014 | 11:32 AM ET

    Senator Nicholas Scutari, D-N.J., discusses the bill he introduced that would allow adults to purchase and grow a limited amount of marijuana for personal use in New Jersey.

  • ADHD big money for big pharma  Wednesday, 12 Mar 2014 | 2:49 PM ET

    CNBC's Sheila Dharmarajan reports 15 percent of high school aged children are diagnosed with ADHD, or attention deficit hyperactivity disorder.

  • Doctor concerned about ADHD misdiagnosis  Wednesday, 12 Mar 2014 | 2:48 PM ET

    Dr. Richard Saul wrote a book called "ADHD Does Not Exist." Saul is certain attention ADHD, or attention deficit hyperactivity disorder exists only in its symptoms. The condition does not exist.

  • Deep discounting eats into Costco's holiday profit Thursday, 6 Mar 2014 | 9:55 AM ET
    A Costco store in Alhambra, Calif.

    Costco Wholesale's profit fell 15 percent, missing estimates, hurt by weaker gross margins in its fresh-food business and some non-foods merchandises.

  • Mylan CEO: Affordable medicine for 7 billion people  Thursday, 27 Feb 2014 | 4:17 PM ET

    Discussing the regulations for affordable medicine, with Mylan CEO Heather Bresch. She also discusses growth strategies for the company.

  • Starbuds of Denver owner Brian Ruden says the next step in his business is to get more "growth capacity" to handle the demand.

  • InterMune CEO: Drug trials bring hope  Tuesday, 25 Feb 2014 | 2:21 PM ET

    InterMune president & CEO Dan Welch says positive drug trial results bring hope to patients with idiopathic pulmonary fibrosis, and discusses the volatility in its stock.